{
  "id": 211274,
  "title": "Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3",
  "url": "https://urgent.news/2026/08/06/braveheart-lands-383m-ipo-to-take-hengrui-cardio-drug-into-phase-3",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-06T06:56:05.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/braveheart-lands-383m-ipo-to-take-hengrui-cardio-drug-into-phase-3/"
  },
  "original_language": "en",
  "account": null,
  "summary": "For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Braveheart Bio priced its",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "Cardiac drug developer Braveheart banks more than $382M in IPO",
        "url": "https://urgent.news/2026/08/06/cardiac-drug-developer-braveheart-banks-more-than-382m-in-ipo",
        "published": "2026-08-06T00:01:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}